News for Cara Therapeutics, Inc. (CARA)

After a rocky start to the spring, Wall Street came roaring back in May. President Trump’s softened tariff stance reignited demand for risk assets, triggering the market’s biggest monthly rally since November 2023. The S&P 500 rose ~6%, nudging back into positive territory for the year. Encouraged by this rebound, John Stoltzfus, chief investment strategist at Oppenheimer, has taken the measure of the markets and holds a positive outlook for the near- to mid-term. “The effects of the stock marke

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. Benzinga Rankings give you vital metrics on any stock – anytime. Thi...

Cara Therapeutics (CARA) has disclosed plans for a structural change to its stock by implementing a 1-for-3 reverse stock split. This adjustment will see its co

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. This article was generated by Benzinga's automated content engine and r...

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. This article was generated by Benzinga's automated content engine and r...

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. This article was generated by Benzinga's automated content engine and r...

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. This article was generated by Benzinga's automated content engine and r...

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. This article was generated by Benzinga's automated content engine and r...

”“Dr. von Moltke brings over 30 years of deep drug development experience and a proven track record of clinical and regulatory success at both large and emergi

**media[568275]**

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. This article was generated by Benzinga's automated content engine and r...

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. Benzinga Rankings give you vital metrics on any stock – anytime. Thi...

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. This article was generated by Benzinga's automated content engine and r...

PR NewswireNEW YORK, Jan. 7, 2025 NEW YORK, Jan. 7, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following comp

Cara Therapeutics (CARA) stock jumps 32% following a 1-for-12 reverse stock split to regain Nasdaq compliance. Read more here.

**media[501337]**

Biopharmaceutical company Cara Therapeutics (CARA) announced on Friday a 1-for-12 reverse stock split to regain compliance with Nasdaq's minimum bid price rule.

Cara Therapeutics enacts reverse stock split

STAMFORD, Conn., Dec. 27, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. ( CARA) (the ”œCompany”), today announced that a 1-for-12 reverse stock split of